The IAS statin literature update will keep you up-to-date with all recent statin publications, using a curated approach to select relevant articles.

**Statin publications February 2022**

**Add on treatments**


5. Groenendaal-van de Meent D, den Adel M, Kerbusch V *et al.* Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies.
Clinical pharmacology in drug development 2022.


Adherence


Atherosclerosis – Plaque-Imaging

1. Verma KP, Marwick T, Duarte C et al. Use of Coronary Computed Tomography or Polygenic Risk Scores to Prompt Action to Reduce Coronary Artery Disease Risk:
Atorvastatin/Rosuvastatin


**Basic science**


Cancer


Children


Cost-effectiveness


CVD

12. Ishii M, Kuramitsu S, Yamanaga K et al. Association of Guideline-Directed Medical Therapy Adherence with Outcomes After Fractional Flow Reserve-Based Deferral of


26. Kandelouei T, Abbasifard M, Imani D et al. Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-


Endothelium/inflammation


Ethnicity


4. Kim S, Choi H, Won CW. Moderate-intensity statin use for primary prevention for more than 5 years is associated with decreased all-cause mortality in 75 years and


17. Ying Q, Chan DC, Pang J et al. PCSK9 inhibition with alirocumab decreases plasma lipoprotein(a) concentration by a dual mechanism of action in statin-treated patients
with very high apolipoprotein(a) concentration. Journal of internal medicine 2022.  

18. Chen YY, Li TC, Li CI et al. Statins Associated with Better Long-Term Outcomes in Aged Hospitalized Patients with COPD: A Real-World Experience from Pay-for-Performance Program. Journal of personalized medicine 2022; 12.  


FH


Genetics


Guidelines


LDL-related parameters


Meta-analyses


Metabolic Syndrome - Diabetes


**New Treatments**


Other


5. Hammad EA, Al-Aqeel S, Elayah E, Jabber D. Assessing content and factors influencing responses to information requests in community pharmacies in Jordan:

**PAD and statins**


**Pleiotropic effects of statins**


6. Sung FC, Yeh YT, Muo CH *et al.* Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study. Cancers 2022; 14.  


**Primary Prevention**


2. Kim S, Choi H, Won CW. Moderate-intensity statin use for primary prevention for more than 5 years is associated with decreased all-cause mortality in 75 years and
older. Archives of gerontology and geriatrics 2022; 100:104644.  


Registry data

http://www.ncbi.nlm.nih.gov/pubmed/?term=35191328

2. Sung FC, Yeh YT, Muo CH et al. Statins Reduce Hepatocellular Carcinoma Risk in Patients with Chronic Kidney Disease and End-Stage Renal Disease: A 17-Year Longitudinal Study. Cancers 2022; 14.  


Renal Disease


Stroke and CNS


Triglycerides/HDL


